🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchMazdutide (LY3305677) — GLORY trials in Chinese population Page 3

Mazdutide (LY3305677) — GLORY trials in Chinese population

TrialNerd_Beth Sun, May 31, 2026 at 8:02 PM 14 replies 547 viewsPage 3 of 3
maria_elpaso
Member
312
1,456
Sep 2024
El Paso, TX
Jun 2, 2026 at 8:22 PM#11
anna.melb_AU said:
Relative and absolute effects need reading together.

This answered a question I did not know how to ask. Adding it to my notes with a link back to this thread.

Last edited: Jun 3, 2026 at 2:22 AM
49 24FitDadDave, RunnerRach, TrialNerd_Beth and 46 others
Reply Quote Save Share Report
hans_munich
Member
534
2,345
Jul 2024
Munich, DE
Jun 4, 2026 at 5:21 AM#12

Adding the clinical framing, because it changes how the question reads. Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third retelling.

Happy to go further on any of that.

48 23alex_tucson, kevin_tulsa, Dr.PainCLE and 45 others
Reply Quote Save Share Report
BariatricNurseD
Senior Member
1,678
7,234
Feb 2024
Dallas, TX
Online
Jun 5, 2026 at 2:19 PM#13
JenPlateau said:
The gap between trial results and real-world results is consistent and it is not fraud.

I read this differently from JenPlateau, on substance rather than tone. The objection nobody has made: this only works if the measurement is doing what we assume it is doing, and that assumption has not been tested here.

47 22josh_phd_bmore, roxy_nash, tony_orlando and 44 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
lucas_SP_BR
Member
456
1,890
Jun 2024
São Paulo, BR
Jun 6, 2026 at 11:19 PM#14

Adding the numbers, since they settle part of this. Keep the original post as written when you update it, and add the correction underneath. An edited-away mistake is invisible to the next person who makes it.

46 21KarenAZ_mom, zoe_NC, Dr.ObesityLA and 43 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Jun 8, 2026 at 8:19 AM#15

Moderator note: leaving this open. It is being argued well and the disagreement is the useful part. Tagging this one for the weekly digest.

45 20PurityPaulOR, MaxMetOK, MounjBrad and 42 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register